Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer.
Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G. Gunther S, et al. Among authors: specht hm. Front Immunol. 2015 Nov 2;6:556. doi: 10.3389/fimmu.2015.00556. eCollection 2015. Front Immunol. 2015. PMID: 26579130 Free PMC article.
Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial.
Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rödel C, Rödel F, Schütz M, Combs SE, Multhoff G. Specht HM, et al. Front Immunol. 2015 Apr 15;6:162. doi: 10.3389/fimmu.2015.00162. eCollection 2015. Front Immunol. 2015. PMID: 25926832 Free PMC article. Review.
Hsp70--a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck.
Gehrmann M, Specht HM, Bayer C, Brandstetter M, Chizzali B, Duma M, Breuninger S, Hube K, Lehnerer S, van Phi V, Sage E, Schmid TE, Sedelmayr M, Schilling D, Sievert W, Stangl S, Multhoff G. Gehrmann M, et al. Among authors: specht hm. Radiat Oncol. 2014 Jun 9;9:131. doi: 10.1186/1748-717X-9-131. Radiat Oncol. 2014. PMID: 24912482 Free PMC article.
Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE. Multhoff G, et al. Clin Cancer Res. 2020 Oct 15;26(20):5368-5379. doi: 10.1158/1078-0432.CCR-20-1141. Epub 2020 Sep 1. Clin Cancer Res. 2020. PMID: 32873573 Clinical Trial.
Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models.
Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G. Bayer C, et al. Among authors: specht hm. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):694-700. doi: 10.1016/j.ijrobp.2013.11.008. Int J Radiat Oncol Biol Phys. 2014. PMID: 24521683
HFSRT of the resection cavity in patients with brain metastases.
Specht HM, Kessel KA, Oechsner M, Meyer B, Zimmer C, Combs SE. Specht HM, et al. Strahlenther Onkol. 2016 Jun;192(6):368-76. doi: 10.1007/s00066-016-0955-2. Epub 2016 Mar 10. Strahlenther Onkol. 2016. PMID: 26964777 English.
20 results